binding affinity News and Research

RSS

SARS-CoV-2 UK variant could be more lethal than others

A new study has assessed the mortality risk of patients infected with the newly emerged UK variant (Lineage B.1.1.7) of SARS-CoV-2. The findings reveal that compared to the previously circulating SARS-CoV-2 variants, the UK variant significantly increases the risk of mortality in a relatively low-risk community population.

15 Mar 2021

Study maps crucial component of long-term immune response to SARS-CoV-2

Researchers in the United States have found that protective antibodies generated against the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)– the agent that causes coronavirus disease 2019 (COVID-19) – also protect against viral variants.

14 Mar 2021

Study identifies three novel binding receptors for SARS-CoV-2

A team of scientists from the United Kingdom recently conducted a large-scale screening of several membrane-bound and soluble host cell receptors to identify novel binding partners for SARS-CoV-2. They have identified three novel receptors expressed on the human cell membrane; of which, one binds to SARS-CoV-2 spike with similar affinity as angiotensin-converting enzyme 2 (ACE2).

12 Mar 2021

Natural virus-induced immunity protective against UK and South African SARS-CoV-2 variants in hamster study

As new variants of SARS-CoV-2 continue to emerge, fueling the continued spread of the COVID-19 pandemic, a new study offers encouragement.

12 Mar 2021

Scientists increase potency of HIV-1 antibody, identify new ways to develop vaccines

Much like coronavirus, circulating HIV-1 viruses mutate into diverse variants that pose challenges for scientists developing vaccines to protect people from HIV/AIDS.

12 Mar 2021

Spike protein mutations in SARS-CoV-2 variants help resist antibody neutralization

Researchers based in Beijing and Shenzhen, China, report that they have identified mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may allow variant strains to avoid neutralization by monoclonal antibodies and convalescent blood plasma.

11 Mar 2021

N501Y mutation in SARS-CoV-2 responsible for increased viral transmission

Researchers at the University of Texas, USA, have confirmed the specific mutation in the B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has allowed for it to be more transmissible than the ancestral strain. The N501Y substitution is one of 8 spike protein substitutions present in the UK variant and has also appeared convergently in the Brazil (P.1) and South Africa (B.1.351) variants.

11 Mar 2021

Could an “ACE2 Triple Decoy” be an alternative approach to neutralizing SARS-CoV-2?

A team of scientists from the USA recently developed a recombinant “Angiotensin converting enzyme 2 (ACE2) Triple Decoy” that can trap SARS-CoV-2 and prevent its propagation inside the host cell.

11 Mar 2021

Rapid increase of UK SARS-CoV-2 variant found in sewage in England between October 2020 to January 2021

A new study confirms the utility of wastewater surveillance as an important new tool in this regard by showing the presence of the UK SARS-CoV-2 variant in wastewater samples from London early in November, with increasing frequency thereafter.

9 Mar 2021

SARS-CoV-2 variants do not substantially affect CD4+ and CD8+ T cell responses, study shows

Researchers from California in the United States have conducted a study showing that important adaptive immune responses to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are not affected by four recently emerged variants of the virus.

3 Mar 2021

Concerning mutation in New York SARS-CoV-2 should be monitored, warn researchers

Researchers at the New York State Department of Health in the United States have said concerning mutations within the B.1.526 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has recently become prevalent in New York State warrant further monitoring.

2 Mar 2021

SARS-CoV-2 UK variant shows low virulence and high shedding in hamster model

A new study compares the pathogenicity and infectiousness of one such variant, the VOC 202012/01 (B.1.1.7 lineage) from the United Kingdom, with the globally dominant D614G mutation-carrying strains.

2 Mar 2021

South African SARS-CoV-2 variant partly resistant to neutralization by mRNA vaccine, says study

A new study deals with the clinical and virological effects of circulating SARS-CoV-2 variants, especially as they affect vaccine efficacy.

26 Feb 2021

Structure of SARS-CoV-2 envelope protein-epithelial cell junction protein complex explains virulence

A new study by researchers at Brookhaven National Laboratory and Stony Brook University in the U.S. describes the key interaction between the viral envelope (E) protein and the human cell junction protein, PALS1. The latter is necessary to establish and maintain cell polarity and tight junctions between cells.

26 Feb 2021

UK and South African SARS-CoV-2 variants show higher binding affinity to host cell receptor

New research by a team of scientists at Stanford University School of Medicine in the U.S. found that both the UK and South African SARS-CoV-2 variants display tighter binding to the ACE2 receptor.

24 Feb 2021

Researchers explore how N501Y mutation in SARS-CoV-2 increases viral transmissibility

Researchers at Erasmus University Medical Center in The Netherlands have explored how and why new variants of SARS-CoV-2 have exhibited heightened infectivity.

24 Feb 2021

Long-lasting B cells do not recognize emerging SARS-CoV-2 variants, shows study

A new analysis of B cells and more than 1,000 different monoclonal antibodies from 8 patients with COVID-19 shows that, contrary to previous hypotheses, protective B cell responses to the SARS-CoV-2 spike protein remain stable and continue to evolve over a 5-month period, many months after the initial period of active viral replication.

23 Feb 2021

COVID-19 may alter host proteins to cause autoimmunity

To better understand the transient and chronic autoimmune symptoms caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, researchers from Memorial Sloan Kettering Cancer Center, Guizhou Medical University, and biotech company Curandis embarked on an endeavor to establish a comprehensive autoantigenome for COVID19.

23 Feb 2021

Two potent SARS-CoV-2 neutralizing antibodies effective against B.1.351 and B.1.1.7 variants

By analyzing the cryoEM structures of antibodies against the SARS-CoV-2 virus, researchers report that the neutralizing capabilities of two antibodies are not affected by new strains as these antibodies target regions of the virus away from the ACE2 binding regions.

23 Feb 2021

Key mutation sites in the SARS-CoV-2 spike protein modulate antibody and ACE2 affinity

A paper recently uploaded to the preprint server bioRxiv by researchers at Chapman University in California (Feb 22nd, 2021) utilized computational methods to screen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutants for affinity with the angiotensin-converting enzyme 2 (ACE2) receptor and monoclonal antibodies REG10987 and REG10933.

23 Feb 2021

binding affinity News and Research

SARS-CoV-2 UK variant could be more lethal than others

Study maps crucial component of long-term immune response to SARS-CoV-2

Study identifies three novel binding receptors for SARS-CoV-2

Natural virus-induced immunity protective against UK and South African SARS-CoV-2 variants in hamster study

Scientists increase potency of HIV-1 antibody, identify new ways to develop vaccines

Spike protein mutations in SARS-CoV-2 variants help resist antibody neutralization

N501Y mutation in SARS-CoV-2 responsible for increased viral transmission

Could an “ACE2 Triple Decoy” be an alternative approach to neutralizing SARS-CoV-2?

Rapid increase of UK SARS-CoV-2 variant found in sewage in England between October 2020 to January 2021

SARS-CoV-2 variants do not substantially affect CD4+ and CD8+ T cell responses, study shows

Concerning mutation in New York SARS-CoV-2 should be monitored, warn researchers

SARS-CoV-2 UK variant shows low virulence and high shedding in hamster model

South African SARS-CoV-2 variant partly resistant to neutralization by mRNA vaccine, says study

Structure of SARS-CoV-2 envelope protein-epithelial cell junction protein complex explains virulence

UK and South African SARS-CoV-2 variants show higher binding affinity to host cell receptor

Researchers explore how N501Y mutation in SARS-CoV-2 increases viral transmissibility

Long-lasting B cells do not recognize emerging SARS-CoV-2 variants, shows study

COVID-19 may alter host proteins to cause autoimmunity

Two potent SARS-CoV-2 neutralizing antibodies effective against B.1.351 and B.1.1.7 variants

Key mutation sites in the SARS-CoV-2 spike protein modulate antibody and ACE2 affinity

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News